Clinical trials: Hospitalized COVID-19
COVID-19
Efficacy and Safety of Ambervin® and Standard Therapy in Hospitalized Patients With COVID-19
This is open-labe randomized multicenter comparative Phase III study conducted in 8 medical facilities. The objective of the study is to assess the efficacy, safety and tolerability of Ambervin for intramuscular and inhaled…
- Trial name
- NCT05656495
- Testing
- Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly, Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled, Standard of care
- Where
- 10 sites in Russia
- Volunteers
- 313 people
- Sponsor
- Promomed, LLC
Volume Outcome Relationship Among COVID-19 Inpatients in US Hospitals
Hospital COVID-19 Surge and Associated Mortality Risk
A retrospective cohort study will be conducted using a large administrative database of U.S. hospitals to understand the volume-outcome relationship among patients hospitalized with COVID-19.
- Trial name
- NCT04688372
- Testing
- Surge Index
- Where
- United States
- Volunteers
- 144,116 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
COVID-19
Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms
There is an urgent need for effective therapies against the novel COVID-19 virus. Studies have shown that amiodarone and verapamil can interfere with coronavirus entry and amplification by blocking ion channels.
- Trial name
- ReCOVery-SIRIO (NCT04351763)
- Testing
- Amiodarone, Verapamil
- Where
- Poland
- Volunteers
- 804 people
- Sponsor
- Nicolaus Copernicus University
Acute Kidney Injury, Covid19
Renal Involvement in Hospitalized Children With COVID-19
Covid-19 is an important human and animal pathogen, it mostly causes respiratory and gastrointestinal symptoms. Clinical features range from a common cold to severe diseases such as severe acute respiratory distress syndrome…
- Conditions
- Acute Kidney Injury, Covid19, Renal Dysfunction, Coronavirus Infection
- Trial name
- RIHCC (NCT04788394)
- Testing
- data review, data comparing
- Where
- Qatar
- Volunteers
- 400 people
- Sponsor
- Hamad Medical Corporation
COVID-19
Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
Investigational medications adjunct to clinical standard of care treatment will be assessed to evaluate safety and effectiveness as an anti-COVID-19 treatment.
- Trial name
- NCT04321993
- Testing
- Baricitinib (janus kinase inhibitor), Remdesivir (antiviral) + barictinib (janus kinase inhibitor), Remdesivir (antiviral)
- Where
- Canada
- Volunteers
- 363 people
- Sponsor
- Lisa Barrett
COVID-19
Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults
Retrospective clinical-epidemiological study aimed at characterizing COVID-19 disease in adults older than 70 years, hospitalized in the "Perpetuo Socorro" Hospital of Albacete (Spain) from 09/03/2020 until 20/04/2020.
- Trial name
- COVID-AGE (NCT04362943)
- Testing
- Baricitinib or Anakinra
- Where
- Spain
- Volunteers
- 576 people
- Sponsor
- Complejo Hospitalario Universitario de Albacete
COVID-19, Coronavirus
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04364737
- Testing
- Convalescent Plasma, Saline solution
- Where
- 9 sites in United States
- Volunteers
- 941 people
- Sponsor
- NYU Langone Health
Covid19, Corona Virus Infection
Nitazoxanide Therapy for Patients With COVID-19 Pneumonia
Multicenter, randomized, placebo-controlled, parallel, blinded, interventional, treatment clinical trial with two arms. Population: 500 Hospitalized patients with pneumonia derived from COVID-19 (Coronavirus Disease-19), either…
- Conditions
- Covid19, Corona Virus Infection, Pneumonia, Viral
- Trial name
- NCT04561219
- Testing
- Nitazoxanide
- Where
- Brazil
- Volunteers
- 500 people
- Sponsor
- Universidade Federal do Rio de Janeiro
COVID19, COVID-19
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.
- Conditions
- COVID19, COVID-19, COVID
- Trial name
- NCT04404361
- Testing
- Pacritinib
- Where
- 21 sites in United States
- Volunteers
- 200 people
- Sponsor
- CTI BioPharma
Covid19
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with anticoagulant, anti-inflammatory and potential…
- Trial name
- ASPEN (NCT04655586)
- Testing
- rNAPc2, Heparin
- Where
- 24 sites in United States, Argentina and 1 more
- Volunteers
- 160 people
- Sponsor
- ARCA Biopharma, Inc.
Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection, Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types
Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes
The COVID-19 pandemic is a global emergency threatening to take millions of lives in the United States and around the world. There is no current vaccine strategy against COVID-19 infection caused by a novel coronavirus named…
- Trial name
- NCT04397900
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- TScan Therapeutics, Inc.
COVID-19
Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19
The primary objective of the study is to determine if Prolastin plus SMT can reduce the proportion of subjects dying or requiring intensive care unit (ICU) admission on or before Day 15 or who are dependent on invasive mechanical…
- Trial name
- NCT04495101
- Testing
- Prolastin, Standard Medical Treatment
- Where
- 9 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Instituto Grifols, S.A.
COVID-19, Methylprednisolone
Investigation of Hospitalisation Times and Mortality According to Drug Dose in Patients Given Systemic Methylprednisolone With a Pre-diagnosis of Covid-19 Pneumonia; Retrospective Study
Aim:There is still not enough data to determine methylprednisolone treatment timing, dosage, duration of use and indication in Covid 19 pneumonia.
- Conditions
- COVID-19, Methylprednisolone, Pneumonia
- Trial name
- NCT04847687
- Testing
- methylprednisolone
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
COVID-19
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo…
- Trial name
- NCT04377711
- Testing
- Ciclesonide
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Covis Pharma S.à.r.l.
SARS-CoV-2
Interferon Lambda Therapy for COVID-19
The main purpose of this research study is to test the safety and effectiveness of an investigational drug peginterferon lambda-1a in treating COVID-19.
- Trial name
- NCT04388709
- Testing
- Peginterferon Lambda-1A
- Sponsor
- Icahn School of Medicine at Mount Sinai
COVID-19, SARS-CoV-2
LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study
COVID-19 is the infectious disease caused by the novel coronavirus known as SARS-CoV-2, that appeared in 2019. The World Health Organisation (WHO) declared the novel coronavirus a pandemic on 11 March 2020.
- Trial name
- LIVE (NCT05282017)
- Where
- 9 sites in Brazil, Colombia and 3 more
- Volunteers
- 792 people
- Sponsor
- AstraZeneca
Covid19
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
- Trial name
- NCT05046561
- Testing
- STRI Formula
- Where
- 13 sites in United States
- Volunteers
- 598 people
- Sponsor
- Eyecheck, Inc.
Corona Virus Infection
Sarilumab COVID-19
Primary Objective: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult participants hospitalized with severe or critical Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04327388
- Testing
- Sarilumab SAR153191
- Where
- 47 sites in Argentina, Brazil and 9 more
- Volunteers
- 420 people
- Sponsor
- Sanofi
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Covid19
Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection
Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection
- Trial name
- NCT04488575
- Testing
- EDP1815
- Where
- 4 sites in United States, Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- Evelo Biosciences, Inc.